Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor
出版年份 2022 全文链接
标题
Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor
作者
关键词
-
出版物
Acta Pharmaceutica Sinica B
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-04-03
DOI
10.1016/j.apsb.2022.03.023
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Polyoxypregnanes as safe, potent and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo
- (2021) Xu Wu et al. Acta Pharmaceutica Sinica B
- Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors
- (2021) Shuo Yuan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance
- (2021) Shuai Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
- (2020) Jinyun Dong et al. DRUG RESISTANCE UPDATES
- Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-a]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators
- (2020) Shuai Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: Total synthesis and discovery of potent MDR reversal agents
- (2019) Senling Feng et al. Acta Pharmaceutica Sinica B
- Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer
- (2019) Jingsheng Yuan et al. CANCER LETTERS
- Combinatory antitumor therapy by cascade targeting of a single drug
- (2019) Aiyun Liu et al. Acta Pharmaceutica Sinica B
- A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell–Intrinsic Transcriptional MSI Traits
- (2019) Simona Corso et al. CANCER RESEARCH
- The use of ultrasound to increase the uptake and cytotoxicity of dual taxane and P-glycoprotein inhibitor loaded, solid core nanoparticles in drug resistant cells
- (2019) John Jackson et al. ULTRASONICS
- Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1
- (2018) Amer Alam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Steroidal dimer by001 inhibits proliferation and migration of esophageal cancer cells via multiple mechanisms
- (2018) Sai-Qi Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
- (2018) Wei Zhang et al. Frontiers in Pharmacology
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade
- (2016) Zhaolin Chen et al. CANCER LETTERS
- Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway
- (2016) Sai-Qi Wang et al. Oncotarget
- DCTPP1 attenuates the sensitivity of human gastric cancer cells to 5-fluorouracil by up-regulating MDR1 expression epigenetically
- (2016) Li-liang Xia et al. Oncotarget
- The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
- (2015) Rishil J. Kathawala et al. DRUG RESISTANCE UPDATES
- Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
- (2015) Renata Silva et al. PHARMACOLOGY & THERAPEUTICS
- Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents
- (2015) Yun-Kai Zhang et al. Oncotarget
- Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway
- (2014) Ting Chen et al. CANCER BIOLOGY & THERAPY
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
- (2013) Ziyad Binkhathlan et al. CURRENT CANCER DRUG TARGETS
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- Recent Advances in the Development of P-gp Inhibitors
- (2012) Christiane Baumert et al. Anti-Cancer Agents in Medicinal Chemistry
- Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance
- (2011) Z. Shi et al. CANCER RESEARCH
- Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer
- (2011) Anniina Koski et al. MOLECULAR THERAPY
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
- (2010) Y.-j. Mi et al. CANCER RESEARCH
- A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
- (2010) R. J. Kelly et al. CLINICAL CANCER RESEARCH
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
- (2009) S. G. Aller et al. SCIENCE
- Verapamil Toxicity Dysregulates the Phosphatidylinositol 3-Kinase Pathway
- (2008) Laura K. Bechtel et al. ACADEMIC EMERGENCY MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started